A good harvest in Qilu!

A few days ago, Qilu Pharmaceutical won the 17th new product of this year: Moxifloxacin Hydrochloride Eye Drops was approved and deemed to have been reviewed, becoming the company's eighth eye drop product
.

Up to now, Qilu Pharmaceutical has been evaluated for 82 varieties, ranking first in the evaluation list for a long time, and a total of 34 varieties have won the bid collection, a large wave of new products is on the way, and 38 new classification varieties are under review

Achieved 17 varieties in half a year, and deeply cultivated the tens of billions of ophthalmology market

On July 5, the official website of NMPA showed that Qilu Pharmaceutical's Moxifloxacin Hydrochloride Eye Drops was approved for listing.
This is the second eye drop approved by the company this year
.

According to data from Meinenet, in 2020, the sales of terminal ophthalmic drugs in urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 10 billion yuan in 2020

Sales of terminal ophthalmic drugs in public medical institutions in China (unit: 100 million yuan)

Source: Mi Nei.

com, China's public medical institutions terminal competition pattern

It is reported that in recent years, Qilu Pharmaceutical has deployed outstanding varieties in the ophthalmology subdivision field and has deepened its ophthalmic product line.

The product line covers glaucoma treatment drugs, ophthalmic anti-infective drugs, dry eye and asthenopia drugs

Currently, Qilu Pharmaceutical has 8 varieties of eye drops, including sodium hyaluronate eye drops, latantimole eye drops, bromfenac sodium eye drops, olopatadine hydrochloride eye drops, brimony tartrate given eye drops, eye drops and dextran 70 moxifloxacin hydrochloride eye drops and so on
.

In addition, three eye drops, including brimonidine timolol eye drops, diquafosol sodium eye drops, and cyclosporine eye drops (II), are under review

Qilu Pharmaceutical's previously approved ophthalmic products

In the first half of 2021, Qilu Pharmaceuticals is still full of gains, and news of drug approvals and reviews continue
.

Based on the drug approval date, Qilu Pharmaceuticals had 17 products approved for marketing in the first half of the year (32 acceptance numbers), and the number will soon exceed 19 in 2020

Among the 17 varieties, there are 5 nervous system drugs, 3 digestive system and metabolic drugs, and 3 anti-infective drugs for systemic use
.

Among them, Qilu Pharmaceutical's rasagiline mesylate tablets and metformin vildagliptin tablets are the first domestic imitations, and the oral dissolving membrane of montelukast sodium is the first domestic one.
Levosimendan injection and emtricitabine capsules , Biapenem for injection and other 3 varieties were the first to be reviewed

2021H1 Qilu Pharmaceutical's products approved for marketing

Source: Meinenet MED2.

0 Chinese Drug Evaluation Database

82 over-rated varieties dominate the screen! 34 varieties won the bid collection

Up to now, Qilu Pharmaceutical has 82 varieties (151 product specifications) passed/deemed to pass the consistency evaluation, of which 37 varieties have been evaluated first in China, and 27 varieties are injections
.

Qilu Pharmaceutical has been in the leading position for a long time in the number of approved products.
The second-ranked Yangzijiang Pharmaceutical Group has 73 products (95 product specifications) reviewed, and China Biopharmaceuticals ranks third with 68 products (105 product specifications).

Among 82 varieties, Emtricitabine Capsules, Warfarin Sodium Tablets, Risperidone Orally Disintegrating Tablets, Isoladine Maleate Tablets, Piperisiride Capsules, Trifluridine Tepipyridine Tablets, Cefprozil Granules , Ondansetron Hydrochloride Tablets, Exemestane Tablets, Brimonidine Tartrate Eye Drops, Granisetron Hydrochloride Injection, Cefepime Hydrochloride for Injection, Biapenem for Injection, Levosimendan Injection The other 14 varieties have been reviewed exclusively by Qilu Pharmaceutical for the time being
.

With a large group of over-reviewed varieties, Qilu Pharmaceutical has gained a lot from participating in national gatherings
.
In the just-concluded fifth batch of centralized procurement, Qilu Pharmaceutical won the bid for 11 varieties, becoming one of the enterprises with the largest number of winning varieties in this centralized procurement
.

Among the five batches of drug procurement carried out by the country, Qilu Pharmaceutical won the bids for 5, 4, 8, 6, and 11 varieties respectively, and a total of 34 varieties won the bid, which is the largest number
.

A large wave of varieties are on the way to review! According to data from Minai.
com, Qilu Pharmaceuticals is reviewing 38 varieties (59 acceptance numbers) of generic drugs under the new registration classification.
After approval, they will be deemed to have passed the consistency evaluation
.
With abundant ammunition reserves, there are still unlimited opportunities for the follow-up centralized procurement of Qilu Pharmaceuticals, and the winning bid profits can also provide financial support for the company's innovation and transformation
.

Qilu Pharmaceutical's new registration classification of generic drugs under review

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

4 license-in a year! 20 new class 1 drugs are eye-catching

On July 5th, Qilu Pharmaceutical submitted a clinical application for QLF31907 for injection, which is the company's seventh new drug clinical application this year
.
According to data from Minaiwang, Qilu Pharmaceutical currently has 20 types of new drugs under development
.
Among them, there are 6 small molecule chemical drugs and 14 large molecule biological drugs
.

Qilu Pharmaceutical is mainly researching new drugs

Qilu Pharma has 3 new drugs approved for clinical use this year, including QL1779 injection, VB4-845 injection and QLS31901 for injection
.
Among them, QLS31901 for injection has started phase I clinical trials, and VB4-845 injection has started phase III clinical trials, which shows that Qilu Pharmaceuticals attaches great importance to these two new drugs
.

VB4-845 injection is a new bladder cancer drug Vicineum introduced by Qilu Pharmaceutical from Sesen Bio in July 2020 for 35 million US dollars
.
Vicineum is a next-generation antibody-drug conjugate (ADC) for the treatment of high-risk non-muscular invasive bladder cancer (NMIBC) that does not respond to Bacille Calmette-Guerin (BCG)
.

It is worth noting that Qilu Pharmaceutical has conducted 4 license-in transactions in one year from July 2020 to the present, which shows its determination to innovate and transform
.

In addition to VB4-845 injection, Qilu Pharmaceutical introduced Quantum Genomics' new hypertension drug Firibastat for US$50 million in October 2020; introduced Cend’s new anticancer drug CEND-1 for US$235 million in February 2021; 2021 4 Introduced an antibody-conjugated drug (ADC) targeting MUC1 from Peptron
.
Among the four new license-in drugs, VB4-845 injection has rapidly started phase III clinical trials, and CEND-1 for injection has been declared IND
.

Data source: Mi Neiwang database, NMPA, etc.

Statistics are as of July 5th, if there are any errors or omissions, please correct me!